Following is a post from DevilDogg84 that contains
Post# of 72446
(Total Views: 236)
Posted On: 08/07/2018 11:37:30 AM
Following is a post from DevilDogg84 that contains info re: Brilacidin and a new wrinkle on the ABSSSI portion of it. Article is extremely recent. The paragraph below the link is the excerpt directly mentioning B and the new wrinkle.
Not sure if anyone has posted this yet.
Biomedical Journal of Scientific & Technical Research
August 06, 2018
https://biomedres.us/pdfs/BJSTR.MS.ID.001536.pdf
Brilacidin is a small molecule arylamide- mimic of AMPs
that shows potent antimicrobial activity against a wide range of
multidrug-resistant Gram-negative and Gram-positive bacteria.
Brilacidin was first developed by Polymedix. Inc. and is now
purchased by Cellceutix Corp. Brilacidin has completed phase
2a and phase 2b trials for the treatment of acute S. aureus skin
infections. Similar to other AMPs brilacidin is a membrane targeting
antimicrobial. It causes membrane disruption and shows efficacy in
a MRSA keratitis model when applied topically; Brilacidin is equally
effective as daptomycin and vancomycin [55].
Cellceutix is also developing CTIX 1278 (structure not revealed)
a defensin- mimetic compound against the drug resistant superbug
Klebsiella pneumoniae. CTIX 1278 is efficacious in a thigh burden
study in a mouse model. The results are encouraging as CTIX 1278
shows similar efficacy compared to carbapenem. 6 LTX 109 is
developed by Lytix Biopharma which focus on topical treatment
of skin infections and nasal eradication of S. aureus. LTX 109 is a
synthetic antimicrobial peptide mimetic which has completed
phase 2 trials for the treatment of impetigo. LTX 109 is active against
a broad range of bacteria including E. coli and S. aureus. LTX 109 is
also active against a panel of drug resistant Gram-positive bacteria
such as MRSA, vancomycin-intermediate resistant, daptomycin
resistant and linezolid resistant strains [56].
I replied that I was surprised as I had thought IPIX shut down their lab work at the current time to focus all efforts and funds towards the current trials.
Not sure if anyone has posted this yet.
Biomedical Journal of Scientific & Technical Research
August 06, 2018
https://biomedres.us/pdfs/BJSTR.MS.ID.001536.pdf
Brilacidin is a small molecule arylamide- mimic of AMPs
that shows potent antimicrobial activity against a wide range of
multidrug-resistant Gram-negative and Gram-positive bacteria.
Brilacidin was first developed by Polymedix. Inc. and is now
purchased by Cellceutix Corp. Brilacidin has completed phase
2a and phase 2b trials for the treatment of acute S. aureus skin
infections. Similar to other AMPs brilacidin is a membrane targeting
antimicrobial. It causes membrane disruption and shows efficacy in
a MRSA keratitis model when applied topically; Brilacidin is equally
effective as daptomycin and vancomycin [55].
Cellceutix is also developing CTIX 1278 (structure not revealed)
a defensin- mimetic compound against the drug resistant superbug
Klebsiella pneumoniae. CTIX 1278 is efficacious in a thigh burden
study in a mouse model. The results are encouraging as CTIX 1278
shows similar efficacy compared to carbapenem. 6 LTX 109 is
developed by Lytix Biopharma which focus on topical treatment
of skin infections and nasal eradication of S. aureus. LTX 109 is a
synthetic antimicrobial peptide mimetic which has completed
phase 2 trials for the treatment of impetigo. LTX 109 is active against
a broad range of bacteria including E. coli and S. aureus. LTX 109 is
also active against a panel of drug resistant Gram-positive bacteria
such as MRSA, vancomycin-intermediate resistant, daptomycin
resistant and linezolid resistant strains [56].
I replied that I was surprised as I had thought IPIX shut down their lab work at the current time to focus all efforts and funds towards the current trials.
(3)
(0)